29 results about "Hypromellose" patented technology

The present invention provides a solid dispersion of compound 1 or a pharmaceutical salt thereof, comprising the compound 1 or the pharmaceutical salt thereof as an active ingredient and a carrier material, wherein the carrier material is selected from one, two, or more of polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl methylcellulose acetate succinate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl methylcellulose, polyethylene glycol, and ethyl cellulose, enabling the drug to have good stability, dissolution, and therapeutic effects. The formulation of the present invention provides rapid drug release and can reduce the oral burden of large-dose tablets on menopausal patients, thereby improving treatment compliance and treatment efficiency.

A rizatriptan microneedle patch, a preparation method therefor, and use thereof. The rizatriptan microneedle patch comprises a substrate and a needle body arranged on a surface of the substrate. The composition of the needle body comprises rizatriptan benzoate and a skeleton material. The skeleton material comprises a combination of dextran and trehalose, copovidone, a combination of polyvinyl alcohol and dextran, a combination of hypromellose and dextran, or a combination of sodium carboxymethyl cellulose and dextran. The rizatriptan microneedle patch has high mechanical strength and cumulative drug permeation.

A pharmaceutical composition comprising: an active pharmaceutical ingredient (API); 1-45 wt% non-gelatin matrix former comprising hydroxypropyl methylcellulose (hypromellose, HPMC), methyl cellulose,

This invention relates to a sustained-release eye drop and its preparation method, belonging to the field of ophthalmic drug technology. The invention provides a self-assembled microparticle comprising an elastin-like peptide and sodium hyaluronate; the molar ratio of the elastin-like peptide to sodium hyaluronate is 5-7:1-2; the amino acid sequence of the elastin-like peptide is shown in SEQ ID NO.1. The self-assembled microparticles of this invention have a sustained-release effect and exhibit synergistic properties with hydroxypropyl methylcellulose. The eye drops prepared by combining these two components possess excellent sustained-release performance, adhesion, and stability, allowing for prolonged application to the eye, effectively solving the problem of short duration of action in existing eye drops.

This invention belongs to the field of biopharmaceutical technology and discloses a tranexamic acid sustained-release composition, its preparation process, and its application. By weight, the composition comprises 100-120 parts tranexamic acid, 14-18 parts sustained-release material, 5-8 parts magnesium stearate, 2-5 parts colloidal silica, and 3-5 parts polyvinyl alcohol. The sustained-release material is selected from a combination of hydroxypropyl cellulose and ethyl cellulose, or a combination of hydroxypropyl methyl cellulose and microcrystalline cellulose, or a combination of sodium carboxymethyl cellulose and hydrogenated vegetable oil. This invention utilizes the synergistic effect of the sustained-release material and the synergistic effect between the sustained-release material and polyvinyl alcohol to maintain zero-order or first-order release of the drug, achieving a steady-state blood drug concentration and prolonging the duration of action, thereby achieving a good sustained-release effect.

The present application relates to the technical field of hydrogen absorption, in particular to a three-layer coated hydrogen absorption oxygen and water blocking microcapsule, a preparation method and application thereof, wherein hydrogen absorption powder is pressed into tablets and then coated with three layers, and the coating solution used in the coating contains hydroxypropyl methyl cellulose, polystyrene and / or reduced graphene oxide. By adding PS and rGO as coating materials and selecting a suitable thickness for coating, the hydrogen absorption microcapsule has the characteristics of hydrogen absorption, oxygen blocking and water blocking.

This invention discloses an amoxicillin capsule and its preparation method, relating to the field of pharmaceutical technology. The preparation method includes the following steps: S1: Wet ball milling of amoxicillin trihydrate and hydroxypropyl methylcellulose E5, followed by spray drying to obtain surface-modified amoxicillin trihydrate micropowder; S2: Mixing the surface-modified amoxicillin trihydrate with a filler; S3: Fluidized bed granulation, including spray granulation using aqueous ethanol as a wetting agent followed by drying; S4: Granulation and mixing, including granulating the dried particles and then adding a disintegrant, a flow aid, and a lubricant; S5: Capsule filling, including capsule filling with controlled ambient humidity. This invention achieves the goals of maintaining the crystal stability of amoxicillin trihydrate, inhibiting hydrothermal degradation, and ensuring dissolution behavior consistent with the original drug by combining wet ball milling of hydroxypropyl methylcellulose E5 with spray drying for surface modification, fluidized bed granulation with aqueous ethanol, and controlling the humidity of the filling environment.

The present application provides a traditional Chinese medicine composition for preventing and treating metabolic-associated fatty liver disease, a capsule, and use. The traditional Chinese medicine composition is prepared from the following starting materials in parts by weight: 1-5 parts of Curcumae Longae Rhizoma extract, 10-20 parts of Puerariae Lobatae Radix extract, 15-30 parts of Salviae Miltiorrhizae Radix et Rhizoma extract, 1-10 parts of Schisandrae Chinensis Fructus extract, and 2-15 parts of Ganoderma extract. The preparation method for the capsule comprises the following steps: mixing the Curcumae Longae Rhizoma extract, the Puerariae Lobatae Radix extract, the Salviae Miltiorrhizae Radix et Rhizoma extract, the Schisandrae Chinensis Fructus extract, the Ganoderma extract, and maltodextrin uniformly, and filling the mixture into a hydroxypropyl methylcellulose hollow capsule to give the capsule. Salviae Miltiorrhizae Radix serves as the sovereign medicinal, Curcumae Longae Rhizoma and Puerariae Lobatae Radix serve as ministerial medicinals, and Schisandrae Chinensis Fructus and Ganoderma serve as adjuvant medicinals, such that the combination of such medicinals achieves the effects of protecting the liver, promoting blood circulation and regulating the flow of qi, promoting the production of body fluids and quenching thirst, tonifying qi for tranquillization, and the like. The present application can effectively prevent and treat metabolic-associated fatty liver disease and can treat non-alcoholic fatty liver disease, especially achieving a significant therapeutic effect on the non-alcoholic simple fatty liver and non-alcoholic steatohepatitis.

The present application relates to a kind of upatin sustained-release tablets and preparation method thereof.The present application uses mannitol, microcrystalline cellulose as filler, hydroxypropyl methyl cellulose as matrix material, malic acid as pH regulator, colloidal silicon dioxide as glidant, magnesium stearate as lubricant, after mixing raw drug with one or more excipients, dry granulation, solve the upatin preparation in the tabletting process due to the hygroscopicity of pH regulator and cause the problem of astringent, sticky and product quality change, shorten the drying time of moisture control in coating process, tablet is more stable in the process of acceleration test and influencing factor test.

The application discloses citrate sildenafil oral dissolving film and a preparation method thereof, and relates to the technical field of medicines. The oral dissolving film comprises citrate sildenafil, the particle size of the citrate sildenafil is 8-12 microns, and the oral dissolving film further comprises hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol-polyethylene glycol copolymer, povidone, a plasticizer, a disintegrant, a colorant, a flavoring agent and essence. The oral dissolving film can solve the technical problems of low drug loading, long preparation time and poor taste of the current citrate sildenafil oral dissolving film. The preparation method can effectively improve the compliance of the citrate sildenafil oral dissolving film by adding a sweetening agent and essence in the preparation process.

A kind of pellet, the pellet includes blank core and drug layer, the drug layer is wrapped in the outer layer of blank core;Wherein, the drug layer includes: vilazodone or its pharmaceutically acceptable salt or ester, and carrier;The carrier includes at least one selected from povidone, copovidone, hypromellose, sucrose and mannitol.The pellet, whether in the environment of pH 6.8 medium, or in the environment of pH 6.8 medium after 0.1M HCl first, has higher solubility, especially can maintain the supersaturated state in the environment of pH 6.8 medium after 0.1M HCl first, therefore, whether with food, or fasting, has higher bioavailability.

This invention relates to a 30 mg bilayer biphasic-release tablet containing merogabarine or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The tablet is a bilayer tablet consisting of an immediate-release layer and a sustained-release layer, wherein the immediate-release layer accounts for 20%–35% of the total drug content, and the sustained-release layer accounts for 65%–80% of the total drug content. The sustained-release layer contains hydroxypropyl methylcellulose K15M or hydroxypropyl methylcellulose K100M and ethylcellulose. Under the conditions of the second method for release determination in the current edition of the Chinese Pharmacopoeia, the tablet has a predetermined 24-hour release window in any of the media selected from pH 1.2, pH 4.5, and pH 6.8, and maintains a small difference in media values ​​at 8 hours and 12 hours, making it suitable for development into an oral sustained-release formulation for once-daily administration.

This invention discloses a ticoraxen solid dispersion, its preparation method, and its applications. Specifically, this invention provides a ticoraxen solid dispersion comprising the active ingredient ticoraxen and a carrier; the carrier is one or more selected from copovidone, povidone, and hydroxypropyl methylcellulose; the weight ratio of ticoraxen to the carrier is 1:(1~6). The ticoraxen solid dispersion of this invention exhibits good release efficiency, and the ticoraxen tablets prepared from it dissolve rapidly and have good stability, making it suitable for industrial-scale production.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a minocycline hydrochloride-melatonin compound colon-targeting capsule and a preparation method thereof. The capsule comprises pellets and a capsule shell, the pellets comprise a drug core and a colon-targeting sustained-release layer wrapped outside the drug core. The drug core contains active ingredients of minocycline hydrochloride and melatonin; the colon-targeting sustained-release layer contains a specially prepared pH-enzyme colon-targeting response agent and a self-prepared plasticizer. The pH-enzyme response agent is based on hydroxypropyl methylcellulose grafted vanillic acid derivatives, and can be degraded in the colon in response to pH changes and azo reductase; the plasticizer has good compatibility with coating materials, and can effectively reduce drug leakage in the stomach and the front end of the intestine. The capsule prepared by the application can significantly improve the gastrointestinal irritation of minocycline hydrochloride, realize targeted release of the drug in the colon, and utilize the synergistic effect of melatonin to reduce the dosage of antibiotics while showing excellent therapeutic effect on ulcerative colitis.

This invention provides a lozenge containing Ganoderma lucidum spore powder polysaccharide and Dendrobium officinale polysaccharide, and its preparation method. By weight, the constituent raw materials include: 15-25 parts of Ganoderma lucidum spore powder polysaccharide-Dendrobium officinale polysaccharide composite nanospheres, 4-9 parts of fructooligosaccharide-γ-aminobutyric acid graft, 10-16 parts of xylitol, 10-16 parts of erythritol, 5-10 parts of microcrystalline cellulose, 2-4 parts of hydroxypropyl methylcellulose, 1-3 parts of γ-aminobutyric acid, 0.3-0.6 parts of magnesium stearate, and 0.2-0.5 parts of citric acid. This lozenge incorporates pharmaceutical excipient applications. By encapsulating the two polysaccharides in the composite nanospheres and other components, it can prevent oxidation, improve bioavailability, synergistically enhance sleep-aiding effects, mask bitterness to optimize taste, and ensure smooth tablet formation and stable storage and transportation.

The present application belongs to the technical field of pharmaceutical excipients, and particularly relates to a high-strength anti-oxygen hydroxypropyl methyl cellulose hollow capsule without gel agent, a preparation method thereof and application. The hollow capsule prepared by the present application contains, by mass percentage of dry solid components, 82.0-93.0 parts of hydroxypropyl methyl cellulose, 2.0-8.0 parts of dialdehyde cellulose nanocrystal, 1.0-4.0 parts of epsilon-polylysine and 2.0-6.0 parts of vitamin E polyethylene glycol succinate. In the capsule framework, the dialdehyde cellulose nanocrystal and epsilon-polylysine are cross-linked in situ to form an interpenetrating network of Schiff base, and the plasticizing and active oxygen scavenging dual effects of vitamin E polyethylene glycol succinate are combined, so that high mechanical strength, low moisture resistance, ultra-low oxygen permeability, rapid disintegration and high antioxidant performance are simultaneously achieved without any exogenous gel agent such as carrageenan, and the prepared hollow capsule is suitable for packaging of oxygen-sensitive drugs and probiotic preparations.

This invention relates to the field of hydrogen absorption technology, specifically to a double-coated hydrogen-absorbing and oxygen-barrier microcapsule, its preparation method, and its application. The hydrogen-absorbing powder is compressed into tablets and then double-coated. The coating solution used in the coating contains hydroxypropyl methylcellulose and / or polystyrene (PS). By adding PS as the coating material and selecting an appropriate coating thickness, the hydrogen-absorbing microcapsule possesses both hydrogen absorption and oxygen-barrier properties.

This invention relates to an oral immunotherapy (OIT) composition comprising granules that contain an allergenic protein, such as peanut protein, along with a humectant, such as trehalose, and a binder, such as hypromellose. The composition may further comprise a filler, such as mannitol and a lubricant, such as stearic acid. OIT compositions, methods of preparing OIT compositions and methods of treatment of food allergy using OIT compositions are provided.

The application discloses a benzalkonium chloride contraceptive gel for killing AIDS pathogens and a preparation method thereof, and belongs to the technical field of biological medicine manufacturing. The benzalkonium chloride contraceptive gel is prepared from water, hydroxypropyl methyl cellulose, polyquaternium-10, modified cyclodextrin, disodium edetate, benzalkonium chloride and glycerol in a specific proportion. In the preparation, the hydroxypropyl methyl cellulose and the polyquaternium-10 are first dispersed by heating, and then the water solution of the modified cyclodextrin, the disodium edetate and the benzalkonium chloride is sucked into the mixture after cooling, and the glycerol is added, and the finished product is obtained through cooling homogenization and vacuum degassing. Compared with the prior art, the amino acid grafted modified cyclodextrin enhances the inclusion and mucosal adhesion performance, the obtained gel has a fast inactivation rate for the AIDS pathogens, a long vaginal retention time, and has the high-efficiency antiviral and long-acting barrier effects, and has low irritation and is safe and reliable.

This invention relates to the field of pharmaceutical formulation technology, and more particularly to an injectable bupivacaine-meroxicam sustained-release solution, its preparation method, and its application. The sustained-release solution comprises the following components in the indicated mass fractions: bupivacaine or a pharmaceutically acceptable salt thereof 1.5%–3.5%; meloxicam or a pharmaceutically acceptable salt thereof 0.03%–0.15%; poloxamer 407 15%–25%; poloxamer 188 1%–8%; hydroxypropyl methylcellulose 0.5%–5%; an osmotic pressure regulator 0.7%–5%; a buffer salt 0.1%–1%; and the balance being water. This invention constructs a thermosensitive in-situ gel system, enabling the formulation to be a flowable solution at room temperature, which rapidly transforms into a semi-solid gel reservoir at body temperature after injection, achieving a long-lasting and stable sustained release of bupivacaine and meloxicam for over 24 hours. All components are safe pharmaceutical excipients with good biocompatibility; the preparation process is simple.

This invention discloses a drug-loaded microcapsule-type controlled-release formulation of trigonelline and its preparation method. The method includes: using microcrystalline cellulose pellets as an inert carrier, sequentially loading a trigonelline drug-loaded layer, a hydroxypropyl methylcellulose isolation layer, and a composite controlled-release membrane layer composed of ethyl cellulose, RS / RL acrylic resin, triethyl citrate, and talc using bottom-spray fluidized bed coating technology; and then filling the mixture into capsules after curing. This invention effectively isolates the drug from the controlled-release membrane layer through the isolation layer and utilizes the RS / RL resin compound to synergistically regulate membrane permeability, achieving stable controlled release of trigonelline. The resulting formulation shows a release rate of no more than 25% in 0.1 mol / L hydrochloric acid after 2 hours, and release rates of 20%-45%, 45%-75%, and 70%-95% after 4 hours, 8 hours, and 12 hours in pH 6.8 buffer solution, respectively. The release behavior is stable and controllable, effectively solving the problem of burst release of highly water-soluble drugs and prolonging the duration of action.

The present invention provides a preparation which remains substantially uncolored even when irradiated with light, by coating a preparation containing the compound represented by formula (I), a salt of said compound, or a crystal of these compounds with a photostable substance and a polymer molecule, using, in particular, at least one substance from among titanium oxide and talc as the photostable substance and hypromellose as the polymer molecule.

This invention discloses a long-acting sustained-release oral patch based on hot-melt extrusion and its preparation method, belonging to the field of oral care technology. The patch is formed from raw materials containing a film-forming material, a filler, and a cooling substance through a hot-melt extrusion process. The film-forming material is selected from at least one of hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, and polyvinyl alcohol; the filler includes at least one of microcrystalline cellulose, pregelatinized starch, mannitol, lactose, and carbomer; the patch has a dense, non-porous structure with a porosity ≤1%, and the cumulative release rate of the cooling substance in simulated saliva (pH 6.8, 37℃) is not less than 80% within 120 minutes. This invention achieves a more than 3-fold improvement in long-acting sustained-release effect, reduces production time from over 20 days to several minutes, and shortens the application time to less than 10 seconds. The product completely dissolves without residue and causes no mucosal irritation, solving the problem of existing technologies failing to balance sustained-release effect, production efficiency, and user experience, making it suitable for industrial production.

This invention provides a birepiperazole oral film, its preparation method, and its application. The birepiperazole oral film comprises the following components: an active pharmaceutical ingredient and a film-forming material. The active pharmaceutical ingredient is 7-[4-(4-benzo[B]thiophene-4-yl-1-piperazine)butoxy]-2(1H)-quinolinone as shown in Formula I and / or a pharmaceutically acceptable salt thereof. The particle size D of the active pharmaceutical ingredient is... 90 ≤70μm; the film-forming material is one or more of hydroxypropyl methylcellulose, polyvinyl alcohol, and hydroxypropyl cellulose; and it does not contain dimethyl silicone oil. The birepiperazole oral film of the present invention has a good dissolution rate, does not have a gritty feel after dissolving in the oral cavity, has a uniform appearance, good flexibility, and does not settle during the preparation of the film solution, and the content uniformity meets the requirements.

The application belongs to the field of pharmaceutical preparations, and particularly relates to a new sildenafil oral dissolving film composition, which comprises sildenafil or a pharmaceutically acceptable salt thereof, a film-forming material, a disintegrant, a plasticizer, a stabilizer and other pharmaceutically acceptable excipients, wherein the film-forming material is a combination of polyvinyl alcohol and hypromellose, and the stabilizer is a small-molecule organic acid. The sildenafil oral dissolving film composition has good film-forming effect, effectively controls the generation and growth of sildenafil impurities, particularly oxidation impurity B, and has good preparation stability.

This invention relates to a 20 mg core-type or core-shell type biphasic-release tablet containing merogabarine or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The tablet is a core-type, compressed-coated tablet, or core-shell type film-coated tablet, comprising an immediate-release portion located in the outer layer or outer coating and a sustained-release portion located in the core, wherein the core is continuously surrounded by the outer layer in the radial direction; the immediate-release portion of the outer layer carries 20%–30% of the total drug content, and the sustained-release portion of the core carries 70%–80% of the total drug content; the core contains hydroxypropyl methylcellulose K15M, polyethylene oxide, and ethylcellulose, suitable for development into an oral sustained-release formulation for once-daily administration.